| Literature DB >> 30071088 |
Molla Abebe1, Mulugeta Melku2, Bamlaku Enawgaw2, Wubet Birhan3, Tekalign Deressa3, Betelihem Terefe2, Habtamu Wondifraw Baynes1.
Abstract
BACKGROUND: Clinical laboratory reference intervals (RIs) are essential for clinical diagnosis, treatment and therapeutic monitoring. Locally established RIs are required to correctly interpret clinical laboratory results. In Ethiopia, clinical laboratory test results are interpreted based on RIs derived from a western population.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30071088 PMCID: PMC6072122 DOI: 10.1371/journal.pone.0201782
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Map of the study area.
Socio-demographic characteristics of blood donors in Amhara National Regional State blood banks, Ethiopia, 2017 (n = 1,175).
| Variables | Blood banks | Total | ||||
|---|---|---|---|---|---|---|
| Debre Markos | Bahir Dar | Gondar | Dessie | |||
| N % | N % | N % | N % | N % | ||
| Male | 176(15.0%) | 158(13.4%) | 144(12.3%) | 166(14.1%) | 644(54.8%) | |
| Female | 127(10.8%) | 135(11.5% | 132(11.2%) | 137(11.7%) | 531(45.2%) | |
| 18–20 | 277(23.6%) | 196(16.7%) | 137(11.7%) | 96(8.2%) | 706(60.1%) | |
| 21–29 | 19(1.6%) | 92(7.8%) | 131(11.1%) | 159(13.5%) | 401(34.1%) | |
| 30–39 | 5(0.4%) | 5(0.4%) | 7(0.6%) | 31(2.6%) | 48(4.1%) | |
| 40–61 | 2(0.2%) | 0(0.0%) | 1(0.1%) | 17(1.4%) | 20(1.7%) | |
| Single | 293(24.9%) | 288(24.5%) | 263(22.4%) | 231(19.7%) | 1075(91.5%) | |
| Married | 10(0.9%) | 5(0.4%) | 13(1.1%) | 72(6.1%) | 100(8.5%) | |
| Student | 292(24.9%) | 257(21.9) | 254(21.6%) | 174(14.8%) | 977(83.1%) | |
| Employed | 11(0.9%) | 34(2.9%) | 13(1.1%) | 67(5.7%) | 125(10.6%) | |
| Other | 0(0.0%) | 2(0.2%) | 9(0.8%) | 62(5.3%) | 73(6.2%) | |
| 303(25.8%) | 293(24.9%) | 276(23.5%) | 303(25.8%) | 1175(100%) | ||
%: percent, N: number.
The RIs of clinical chemistry parameters among blood donors in Amhara National Regional State, Ethiopia, 2017 (N = 1,175; Male = 644, and Female = 531).
| Analytes | Unit | Sex | Mean | 95% CI of Mean | Median | 25th–75th percentile | 2.5th–97.5th percentile, RI | p-value |
|---|---|---|---|---|---|---|---|---|
| U/L | Combined | 15.71 | 15.22,16.24 | 14.0 | 10.0,19.0 | 5.0–39.0 | <0.0001 | |
| Male | 17.15 | 16.50,17.88 | 15.0 | 12.0,20.0 | 5.13–42.88 | |||
| Female | 13.97 | 13.34,14.74 | 12.0 | 9.0,16.0 | 4.3–37.0 | |||
| U/L | Combined | 22.84 | 22.35,23.36 | 21.0 | 17.0,27.0 | 11.0–46.0 | <0.001 | |
| Male | 24.13 | 23.46–24.77 | 23.0 | 19.0,28.0 | 12.13–46.88 | |||
| Female | 21.27 | 20.55,22.04 | 19.0 | 16.0,24.0 | 10.0–43.8 | |||
| U/L | Combined | 199.5 | 194.13,205.24 | 174.0 | 141.75,230.0 | 87.0–451.28 | <0.0001 | |
| Male | 217.55 | 209.09,225.91 | 186.0 | 147.0,269.0 | 77.20–475.8 | |||
| Female | 177.56 | 171.28,184.07 | 162.0 | 134.0,204.0 | 89.0–381.0 | |||
| U/L | Combined | 124.84 | 120.64,128.98 | 109.0 | 66.0,172.0 | 29.0–299.0 | <0.0001 | |
| Male | 131.07 | 125.45,136.91 | 121.5 | 69.0,179.75 | 29.0–309.8 | |||
| Female | 117.29 | 111.34,123.32 | 102.0 | 61.0,167.0 | 29.0–287.9 | |||
| U/L | Combined | 18.39 | 17.63,19.15 | 15.0 | 11.0,21.0 | 7.0–58.0 | <0.0001 | |
| Male | 21.08 | 20.06,22.27 | 17.0 | 13.0,24.0 | 7.0–69.8 | |||
| Female | 15.13 | 14.34,15.97 | 13.0 | 10.0,17.0 | 6.0–39.1 | |||
| mg/dl | Combined | 0.22 | 0.21,0.22 | 0.19 | 0.13,0.26 | 0.02–0.61 | <0.0001 | |
| Male | 0.25 | 0.23,0.26 | 0.21 | 0.15,0.3 | 0.04–0.68 | |||
| Female | 0.18 | 0.17,0.19 | 0.17 | 0.11,0.23 | 0.01–0.49 | |||
| mg/dl | Combined | 0.35 | 0.34,0.37 | 0.29 | 0.21,0.42 | 0.1–1.1 | <0.0001 | |
| Male | 0.40 | 0.38,0.42 | 0.33 | 0.24,0.46 | 0.11–1.18 | |||
| Female | 0.30 | 0.28,0.32 | 0.25 | 0.18,0.35 | 0.08–0.91 | |||
| mg/dl | Combined | 7.59 | 7.52,7.65 | 7.5 | 6.8,8.3 | 5.7–9.6 | <0.0001 | |
| Male | 7.70 | 7.61,7.78 | 7.7 | 6.9,8.5 | 5.7–9.7 | |||
| Female | 7.45 | 7.37,7.54 | 7.4 | 6.7,8.2 | 5.6–9.47 | |||
| g/dl | Combined | 5.0 | 4.97,5.04 | 5.0 | 4.6,5.4 | 3.7–6.2 | <0.0001 | |
| Male | 5.08 | 5.03,5.13 | 5.1 | 4.6,5.5 | 3.7–6.2 | |||
| Female | 4.9 | 4.86,4.95 | 5.0 | 4.5,5.3 | 3.6–6.1 | |||
| mg/dl | Combined | 134.73 | 132.92,136.56 | 132.0 | 113.0,154 | 80.4–206.6 | <0.0001 | |
| Male | 132.79 | 130.39,135.31 | 130.0 | 111.0,150.0 | 78.13–211.75 | |||
| Female | 137.08 | 134.41,139.71 | 135.0 | 115.0,159.0 | 83.6–202.7 | |||
| mg/dl | Combined | 96.97 | 94.28,99.80 | 86.0 | 61.0,122.0 | 36.0–215.6 | <0.0001 | |
| Male | 101.41 | 97.80,105.00 | 90.0 | 63.25,128.75 | 36.0–221.9 | |||
| Female | 91.59 | 87.61,95.20 | 80.0 | 58.0,115.0 | 35.3–201.5 | |||
| mg/dl | Combined | 0.79 | 0.78,0.80 | 0.79 | 0.7,0.88 | 0.47–1.12 | <0.001 | |
| Male | 0.83 | 0.82,0.84 | 0.83 | 0.75,0.92 | 0.48–1.13 | |||
| Female | 0.75 | 0.74,0.76 | 0.74 | 0.66,0.82 | 0.47–1.09 | |||
| mg/dl | Combined | 23.35 | 22.91,23.78 | 23.0 | 18.0,28.0 | 11.0–41.0 | <0.0001 | |
| Male | 24.53 | 23.95,25.17 | 24.0 | 19.0,29.0 | 12.0–43.0 | |||
| Female | 21.92 | 21.28,22.51 | 21.0 | 17.0,26.0 | 10.0–38.7 | |||
| mg/dl | Combined | 4.16 | 4.10,4.23 | 4.0 | 3.3,4.9 | 2.34–6.60 | <0.0001 | |
| Male | 4.55 | 4.47,4.63 | 4.4 | 3.8,5.2 | 2.7–6.9 | |||
| Female | 3.68 | 3.60,3.76 | 3.5 | 3.1,4.2 | 2.1–5.9 |
*P-value: Wilcoxon rank-sum test for male versus female; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; CI: confidence interval; dl: Decilitre; g: Gram; GGT: Gamma glutamyltransferase; L: litre; mg: Milligram; RI: Reference interval; SGOT: Serum glutamate oxaloacetate transaminase; SGPT: Serum glutamate pyruvate transaminase; U: Unit.
The 90% CI of reference limits of clinical chemistry parameters RIs among blood donors in Amhara National Regional State, Ethiopia, 2017 (N = 1,175; Male = 644 and Female = 531).
| Analytes | Unit | Sex | Range | 2.5th–97.5th percentile, RI | 90% CI (lower | 90% CI (upper |
|---|---|---|---|---|---|---|
| U/L | Combined | 2.0–62.0 | 5.0–39.0 | 4.0,5.0 | 36.0,45.0 | |
| Male | 3.0–60.0 | 5.13–42.88 | 5.0,6.0 | 36.58,48.57 | ||
| Female | 2.0–62.0 | 4.3–37.0 | 4.0,5.0 | 32.7,42.61 | ||
| U/L | Combined | 4.0–64.0 | 11.0–46.0 | 10.0,11.4 | 42.2,49.0 | |
| Male | 4.0–63.0 | 12.13–46.88 | 12.0,13.0 | 43.0,51.0 | ||
| Female | 8.0–64.0 | 10.0–43.8 | 10.0,11.0 | 39.0,49.0 | ||
| U/L | Combined | 10.0–583.0 | 87.0–451.28 | 74.75,93.0 | 433.0,474.0 | |
| Male | 10.0–583.0 | 77.2–475.8 | 53.0,97.72 | 453.0,495.48 | ||
| Female | 34.0–575.0 | 89.0–381.0 | 80.11,93.8 | 334.41,403.0 | ||
| U/L | Combined | 10.0–367.0 | 29.0–299.0 | 26.4,32.0 | 286.0,310.0 | |
| Male | 10.0–367.0 | 29.0–309.8 | 25.8,32.0 | 289.55,317.38 | ||
| Female | 10.0–357.0 | 29.0–287.9 | 24.2,33.0 | 254.0,302.38 | ||
| U/L | Combined | 1.0–96.0 | 7.0–58.0 | 6.0,7.0 | 53.0,67.0 | |
| Male | 1.0–96.0 | 7.0–69.8 | 7.0,8.0 | 57.65,76.0 | ||
| Female | 4.0–89.0 | 6.0–39.1 | 6.0,7.0 | 31.48,49.73 | ||
| mg/dl | Combined | 0.0–0.85 | 0.02–0.61 | 0.01,0.04 | 0.53,0.66 | |
| Male | 0.0–0.85 | 0.04–0.68 | 0.02,0.06 | 0.6,0.71 | ||
| Female | 0.0–0.85 | 0.01–0.49 | 0.0,0.02 | 0.41,0.59 | ||
| mg/dl | Combined | 0.02–1.89 | 0.1–1.1 | 0.08,0.10 | 0.97,1.18 | |
| Male | 0.02–1.89 | 0.11–1.18 | 0.09,0.13 | 1.1,1.28 | ||
| Female | 0.05–1.39 | 0.08–0.91 | 0.73,0.1 | 0.78,1.04 | ||
| mg/dl | Combined | 4.4–10.9 | 5.7–9.6 | 5.6,5.8 | 9.5,9.7 | |
| Male | 4.4–10.9 | 5.7–9.7 | 5.6,5.9 | 9.6,9.9 | ||
| Female | 5.1–10.7 | 5.6–9.47 | 5.43,5.8 | 9.21,9.6 | ||
| g/dl | Combined | 3.0–7.3 | 3.7–6.2 | 3.6,3.84 | 6.1,6.2 | |
| Male | 3.0–7.3 | 3.7–6.2 | 3.6,3.9 | 6.1,6.3 | ||
| Female | 3.1–6.6 | 3.6–6.1 | 3.55,3.83 | 6.0,6.2 | ||
| mg/dl | Combined | 54.0–242.0 | 80.4–206.60 | 77.0,83.0 | 201.0,212.0 | |
| Male | 55.0–242.0 | 78.13–211.75 | 74.0,82.0 | 202.25,215.66 | ||
| Female | 54.0–235.0 | 83.6–202.7 | 78.3,86.0 | 194.81,210.0 | ||
| mg/dl | Combined | 24.0–255.0 | 36.0–215.6 | 35.0,37.4 | 208.2,221.6 | |
| Male | 24.0–255.0 | 36.0–221.9 | 33.66,39.0 | 213.0,233.84 | ||
| Female | 24.0–250 | 35.3–201.5 | 34.48,38.0 | 190.42,216.07 | ||
| mg/dl | Combined | 0.16–1.46 | 0.47–1.12 | 0.42,0.50 | 1.08,1.15 | |
| Male | 0.16–1.46 | 0.48–1.13 | 0.38,0.55 | 1.1,1.15 | ||
| Female | 0.18–1.36 | 0.47–1.09 | 0.4,0.51 | 1.01,1.17 | ||
| mg/dl | Combined | 6.0–56.0 | 11.0–41.0 | 10.4,12.0 | 40.0,43.0 | |
| Male | 8.0–56.0 | 12.0–43.0 | 12.0,13.0 | 40.0,44.0 | ||
| Female | 6.0–50.0 | 10.0–38.7 | 10.0,11.0 | 35.03,41.48 | ||
| mg/dl | Combined | 1.7–10.0 | 2.34–6.60 | 2.24,2.4 | 6.5,6.8 | |
| Male | 1.8–10.0 | 2.7–6.9 | 2.5,2.8 | 6.66,7.0 | ||
| Female | 1.7–7.3 | 2.1–5.9 | 2.0,2.24 | 5.5,6.39 |
ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; CI: confidence interval; dl: Decilitre; g: Gram; GGT: Gamma glutamyltransferase; L: litre; mg: Milligram; RI: Reference interval; SGOT: Serum glutamate oxaloacetate transaminase; SGPT: Serum glutamate pyruvate transaminase; U: Unit.
Comparison of clinical chemistry parameter RIs of this study against manufacturer ranges and other similar studies.
| Analytes | Sex | Current study | Manufacturer | Northwest Ethiopia [ | Southwest Ethiopia [ | Uganda [ | Tanzania [ | Ghana [ | USA [ |
|---|---|---|---|---|---|---|---|---|---|
| Combined | 5.0–39.0 | NA | 6.0–43.0 | 11.0–54.0 | 6.6–42.8 | 7.7–48.3 | 7–51 | 0–35 | |
| Male | 5.13–42.88 | 0–42 | 6.0–44.6 | 11.2–56.0 | 7.2–43.3 | 9.1–55. | 8–54 | NA | |
| Female | 4.3–37.0 | 0–32 | 3.0–30.0 | 10.1–54.0 | 5.3–39.9 | 6.7–44.9 | 6–51 | NA | |
| Combined | 11.0–46.0 | NA | 9.0–38.0 | 12.0–59.0 | 12.3–34.8 | 14.3–48.1 | 14–51 | 0–35 | |
| Male | 12.13–46.88 | 0–37 | 10.5–39.0 | 13.0–59.5 | 13.2–35.9 | 15.2–53.4 | 17–60 | NA | |
| Female | 10.0–43.8 | 0–31 | 6.0–32.1 | 12.0–59.9 | 11.4–28.8 | 13.5–35.2 | 13–48 | NA | |
| Combined | 87.0–451.28 | NA | 52.4–237.0 | 63.0–376.0 | 44–151 | 45.6–158.4 | 85–241 | 30–120 | |
| Male | 77.2–475.8 | 80–306 | 55.3–237.2 | 55.8–362.9 | 42–159 | 45.4–170.4 | 101–353 | NA | |
| Female | 89.0–381.0 | 64–306 | 49.0–236.0 | 70.4–384.4 | 47–160 | 45.3–155.0 | 82–293 | NA | |
| Combined | 29.0–299.0 | 0–220 | 48.0–188.8 | NA | 45.6–173.6 | 42.8–164.4 | 32–139 | 60–180 | |
| Male | 29.0–309.8 | NA | 45.3–190.0 | NA | 46–175 | 49.6–180.1 | 34–137 | NA | |
| Female | 29.0–287.9 | NA | 48.0–187.9 | NA | 44–177 | 41.8–160.4 | 30–139 | NA | |
| Combined | 7.0–58.0 | 9–64 | NA | NA | 8.5–68.5 | 8.1–107.8 | 7–61 | 1–94 | |
| Male | 7.0–69.8 | NA | NA | NA | 8.7–70.7 | 9.3–120.8 | 9–71 | NA | |
| Female | 6.0–39.1 | NA | NA | NA | 8.0–41.3 | 7.3–51.8 | 6–53 | NA | |
| Combined | 0.02–0.61 | 0–0.2 | 0.01–0.80 | NA | 0.02–0.4 | 0.04–0.48 | 0.05–0.23 | 0.1–0.3 | |
| Male | 0.04–0.68 | NA | 0.02–0.84 | NA | 0.1–0.5 | 0.05–0.49 | 0.05–0.24 | NA | |
| Female | 0.01–0.49 | NA | 0.01–0.71 | NA | 0.0–0.4 | 0.04–0.34 | 0.04–0.22 | NA | |
| Combined | 0.1–1.1 | 0.1–1.2 | 0.26–2.20 | NA | 0.4–2.5 | 0.30–2.40 | 0.17–1.51 | 0.3–1.0 | |
| Male | 0.11–1.18 | NA | 0.27–2.20 | NA | 0.4–2.6 | 0.35–2.46 | 0.22–1.87 | NA | |
| Female | 0.08–0.91 | NA | 0.21–2.20 | NA | 0.3–1.9 | 0.26–1.83 | 0.16–1.56 | NA | |
| Combined | 5.7–9.6 | 6.6–8.7 | 5.3–8.6 | 4.4–11.6 | 6.6–8.9 | 6.6–8.5 | 5.1–8.7 | 5.5–8.0 | |
| Male | 5.7–9.7 | NA | 5.3–8.7 | 4.0–11.4 | 6.5–8.9 | 6.7–8.5 | 4.7–8.6 | NA | |
| Female | 5.6–9.47 | NA | 5.3–8.6 | 4.6–11.7 | 6.8–9.0 | 6.6–8.6 | 5.5–8.7 | NA | |
| Combined | 3.7–6.2 | 3.8–5.1 | NA | NA | 3.8–5.3 | 3.6–5.0 | 3.3–5.0 | 3.5–5.5 | |
| Male | 3.7–6.2 | NA | NA | NA | 3.9–5.4 | 3.7–5.1 | 3.3–5.0 | NA | |
| Female | 3.6–6.1 | NA | NA | NA | 3.7–5.2 | 3.6–4.9 | 3.4–5.0 | NA | |
| Combined | 80.4–206.60 | 0–190 | NA | 55.0–276.0 | 91–233 | 95.5–213.8 | 77.3–208.1 | <200 | |
| Male | 78.13–211.75 | NA | NA | 52.1–252.2 | 90–235 | 89.7–219.3 | 69.6–193.3 | NA | |
| Female | 83.6–202.7 | NA | NA | 58.0–286.4 | 100–230 | 109–212.7 | 81.2–216.6 | NA | |
| Combined | 36.0–215.6 | 0–150 | NA | 41.0–264.0 | 39–281 | 34.5–255.1 | 35.4–194.9 | <160 | |
| Male | 36.0–221.9 | NA | NA | 41.3–275.8 | 39–299 | 34.5–266.6 | 35.4–194.9 | NA | |
| Female | 35.3–201.5 | NA | NA | 41.0–261.2 | 34–206 | 33.7–193.1 | 35.4–186 | NA | |
| Combined | 0.47–1.12 | NA | 0.23–1.22 | 0.32–1.32 | 0.5–1.2 | 0.48–1.02 | 0.55–1.33 | <1.5 | |
| Male | 0.48–1.13 | 0.6–1.1 | 0.20–1.29 | 0.3–1.4 | 0.6–1.2 | 0.54–1.09 | 0.63–1.35 | NA | |
| Female | 0.47–1.09 | 0.5–0.9 | 0.25–1.08 | 0.3–1.3 | 0.5–0.9 | 0.45–0.92 | 0.53–1.24 | NA | |
| Combined | 11.0–41.0 | 10–50 | NA | 4.6–35.0 | 9.9–33.2 | 9.1–29.5 | 5.4–34.2 | 21.4–42.9 | |
| Male | 12.0–43.0 | NA | NA | 4.6–34.5 | 10.1–33.9 | 9.3–29.8 | 5.4–37.2 | NA | |
| Female | 10.0–38.7 | NA | NA | 4.5–35.8 | 9.4–30.2 | 8.8–27.4 | 5.4–32.4 | NA | |
| Combined | 2.34–6.60 | NA | NA | 2.0–7.4 | 3.3–7.8 | 2.8–7.5 | 1.5–6.7 | NA | |
| Male | 2.7–6.9 | 3.4–7.0 | NA | 2.5–7.9 | 3.5–8.0 | 3.3–7.7 | 2.1–7.0 | 2.5–8.0 | |
| Female | 2.1–5.9 | 2.4–5.7 | NA | 2.0–7.2 | 3.0–6.8 | 2.5–6.1 | 1.4–6.4 | 1.5–6.0 |
ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; CI: confidence interval; dl: Decilitre; g: Gram; GGT: Gamma glutamyltransferase; L: litre; mg: Milligram; NA: Not available; SGOT: Serum glutamate oxaloacetate transaminase; SGPT: Serum glutamate pyruvate transaminase; USA: United States of America; U: Unit.